ETHRIS

ETHRIS is a biotechnology company based in Planegg, Bavaria, Germany, that develops messenger RNA therapeutics and vaccines focused on treating severe respiratory diseases. The organization utilizes proprietary non-immunogenic mRNA technology to deliver stabilized treatments directly into the respiratory system through optimized formulation and nebulization techniques. Its clinical development pipeline primarily targets immuno-modulation and mRNA-based protein replacement therapies designed to address complex medical conditions in respiratory care. Operating as an independent enterprise funded through grants and equity investments, the company maintains a workforce of 70 employees and generates an estimated $23.6 million in annual revenue. To advance its clinical programs, ETHRIS recently secured a $5 million funding commitment from the Gates Foundation. This capital injection is allocated to prepare the company's lead therapeutic candidate, designated as ETH47, for an upcoming Phase 2 clinical study.